These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 26809286)
61. Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis. Tramacere I; Del Giovane C; Filippini G JAMA; 2016 Jan; 315(4):409-10. PubMed ID: 26813214 [TBL] [Abstract][Full Text] [Related]
64. Characterization of Axonal Disease in Patients with Multiple Sclerosis Using High-Gradient-Diffusion MR Imaging. Huang SY; Tobyne SM; Nummenmaa A; Witzel T; Wald LL; McNab JA; Klawiter EC Radiology; 2016 Jul; 280(1):244-51. PubMed ID: 26859256 [TBL] [Abstract][Full Text] [Related]
65. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Ho PP; Steinman L Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456 [TBL] [Abstract][Full Text] [Related]
67. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Schläger C; Körner H; Krueger M; Vidoli S; Haberl M; Mielke D; Brylla E; Issekutz T; Cabañas C; Nelson PJ; Ziemssen T; Rohde V; Bechmann I; Lodygin D; Odoardi F; Flügel A Nature; 2016 Feb; 530(7590):349-53. PubMed ID: 26863192 [TBL] [Abstract][Full Text] [Related]
68. Regulatory T cell number in multiple sclerosis patients: A meta-analysis. Noori-Zadeh A; Mesbah-Namin SA; Bistoon-Beigloo S; Bakhtiyari S; Abbaszadeh HA; Darabi S; Rajabibazl M; Abdanipour A Mult Scler Relat Disord; 2016 Jan; 5():73-6. PubMed ID: 26856947 [TBL] [Abstract][Full Text] [Related]
69. An initial top-down proteomic analysis of the standard cuprizone mouse model of multiple sclerosis. Partridge MA; Gopinath S; Myers SJ; Coorssen JR J Chem Biol; 2016 Jan; 9(1):9-18. PubMed ID: 26855677 [TBL] [Abstract][Full Text] [Related]
70. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Opsahl JA; Vaudel M; Guldbrandsen A; Aasebø E; Van Pesch V; Franciotta D; Myhr KM; Barsnes H; Berle M; Torkildsen Ø; Kroksveen AC; Berven FS Proteomics; 2016 Apr; 16(7):1154-65. PubMed ID: 26841090 [TBL] [Abstract][Full Text] [Related]
71. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I; J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718 [TBL] [Abstract][Full Text] [Related]
72. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. De Mercanti S; Rolla S; Cucci A; Bardina V; Cocco E; Vladic A; Soldo-Butkovic S; Habek M; Adamec I; Horakova D; Annovazzi P; Novelli F; Durelli L; Clerico M Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e194. PubMed ID: 26819963 [TBL] [Abstract][Full Text] [Related]
73. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. Jiang W; St-Pierre S; Roy P; Morley BJ; Hao J; Simard AR J Immunol; 2016 Mar; 196(5):2095-108. PubMed ID: 26810225 [TBL] [Abstract][Full Text] [Related]
74. Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility. An H; Lim C; Guillemin GJ; Vollmer-Conna U; Rawlinson W; Bryant K; Tedla N PLoS One; 2016; 11(2):e0149200. PubMed ID: 26871720 [TBL] [Abstract][Full Text] [Related]
75. Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER. Triche EW; Ruiz JA; Olson KM; Lo AC Clin Neuropharmacol; 2016; 39(2):73-80. PubMed ID: 26818040 [TBL] [Abstract][Full Text] [Related]
76. Depression during multiple sclerosis relapse: relation to disability and relapse severity. Šabanagić-Hajrić S; Suljić E; Sulejmanpašić-Arslanagić G Med Glas (Zenica); 2016 Feb; 13(1):44-9. PubMed ID: 26827706 [TBL] [Abstract][Full Text] [Related]
77. Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis. Jafarzadeh A; Mahdavi R; Jamali M; Hajghani H; Nemati M; Ebrahimi HA Oman Med J; 2016 Jan; 31(1):40-5. PubMed ID: 26813806 [TBL] [Abstract][Full Text] [Related]
78. A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. Carulli C; Nistri L; Bracco L; Giannini M; Amato MP Clin Cases Miner Bone Metab; 2015; 12(3):257-9. PubMed ID: 26811707 [TBL] [Abstract][Full Text] [Related]
79. The association of pathological laughing and crying and cognitive impairment in multiple sclerosis. Hanna J; Feinstein A; Morrow SA J Neurol Sci; 2016 Feb; 361():200-3. PubMed ID: 26810543 [TBL] [Abstract][Full Text] [Related]
80. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. Río J; Ruiz-Peña JL J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]